Want to see ESTA full AI Analyst Report?
ESTA Stock Chart & Stats
$71.80
-$0.46(-0.50%)
At close: 4:00 PM EDT
$71.80
-$0.46(-0.50%)
Day’s Range― - ―
52-Week Range$47.00 - $97.59
Previous CloseN/A
Volume49.76K
Average Volume (3M)375.48K
Market Cap
$1.90B
Enterprise Value$2.78B
Total Cash (Recent Filing)$71.16M
Total Debt (Recent Filing)$263.67M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Oct 29, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding29,801,891
10 Day Avg. Volume432,787
30 Day Avg. Volume375,475
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.47
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue11.30
Enterprise Value/Gross Profit16.03
Enterprise Value/Ebitda-300.83
Forecast
1Y Price Target
$96.88Price Target Upside34.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$270.22M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginThe combination of rising revenue and a roughly 70% gross margin indicates meaningful product demand and attractive unit economics. If maintained, this gross-profit base can fund commercial expansion, support operating leverage, and provide a foundation for eventual profitability as scale improves.
Narrowing Losses And Cash BurnSubstantial reduction in losses shows that operating performance is moving in the right direction, while improving free cash flow suggests tighter investment or better efficiency. Continued progress could shorten the path to break-even and reduce future dependence on external funding.
Long-term Silicone Supply AgreementExtending access to a critical production input through 2031 improves planning visibility and supports business continuity. The agreement can reduce uncertainty around supply and specified product manufacturing, helping Establishment Labs execute its growth strategy over multiple years.
Bears Say
Unprofitable Operating ModelStrong gross margins have not yet translated into positive operating or net earnings, indicating that selling, administrative, development, or other costs remain too high relative to current scale. Persistent losses limit internally generated capital and leave execution dependent on further improvement.
Persistent Negative Cash GenerationOngoing negative operating cash flow means the company is not yet funding its activities from recurring operations. Although cash burn has improved, continued deficits can consume financial flexibility and may require external funding or balance-sheet resources until sustained cash break-even is achieved.
Thin Equity Base And Negative ReturnsA relatively small equity base compared with total assets leaves less capital cushion against operating setbacks, while deeply negative returns show that shareholder capital is not yet generating value. Restoring profitability is important for strengthening equity and improving long-term resilience.
Establishment Labs Holdings News
ESTA FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was $47.00 and its highest was $97.59 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is $1.90B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Oct 29, 2026 which is in 3 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on Aug 06, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.337 by -$0.053.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.26.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,801,891 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.337. Following the earnings report the stock price went down -13.37%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in ESTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.88 (34.92% Upside)
$96.88 (34.92% Upside)
Blogger Sentiment
Bullish
ESTA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 119.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.65%
12-Months-Change
Fundamentals
Return on Equity
-203.88%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
ESTA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all ESTA earnings summariesESTA Stock 12 Month Forecast
Average Price Target
$96.88
▲(34.92% Upside)
Technical Analysis
Ownership Overview
17.80% Insiders
5.95% Mutual Funds
0.38% Other Institutional Investors
70.15% Public Companies and
Individual Investors